Osteoarthritis Pain - Pipeline Review, H2 2017

Date: October 10, 2017
Pages: 224
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O0482EE8AA0EN
Leaflet:

Download PDF Leaflet

Osteoarthritis Pain - Pipeline Review, H2 2017
Osteoarthritis Pain - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 23, 9, 1, 23, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Osteoarthritis Pain - Overview
Osteoarthritis Pain - Therapeutics Development
Osteoarthritis Pain - Therapeutics Assessment
Osteoarthritis Pain - Companies Involved in Therapeutics Development
Osteoarthritis Pain - Drug Profiles
Osteoarthritis Pain - Dormant Projects
Osteoarthritis Pain - Discontinued Products
Osteoarthritis Pain - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Osteoarthritis Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteoarthritis Pain - Pipeline by AbbVie Inc, H2 2017
Osteoarthritis Pain - Pipeline by Achelios Therapeutics Inc, H2 2017
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2017
Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2017
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, H2 2017
Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Array BioPharma Inc, H2 2017
Osteoarthritis Pain - Pipeline by Astellas Pharma Inc, H2 2017
Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H2 2017
Osteoarthritis Pain - Pipeline by BELLUS Health Inc, H2 2017
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Osteoarthritis Pain - Pipeline by Cara Therapeutics Inc, H2 2017
Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, H2 2017
Osteoarthritis Pain - Pipeline by Chromocell Corp, H2 2017
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Osteoarthritis Pain - Pipeline by Flexion Therapeutics Inc, H2 2017
Osteoarthritis Pain - Pipeline by Genzyme Corp, H2 2017
Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H2 2017
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2017
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals LLC, H2 2017
Osteoarthritis Pain - Pipeline by Marina Biotech Inc, H2 2017
Osteoarthritis Pain - Pipeline by Medestea Research & Production SpA, H2 2017
Osteoarthritis Pain - Pipeline by MedImmune LLC, H2 2017
Osteoarthritis Pain - Pipeline by Merck & Co Inc, H2 2017
Osteoarthritis Pain - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Osteoarthritis Pain - Pipeline by Pfizer Inc, H2 2017
Osteoarthritis Pain - Pipeline by ProteoThera Inc, H2 2017
Osteoarthritis Pain - Pipeline by pSivida Corp, H2 2017
Osteoarthritis Pain - Pipeline by RaQualia Pharma Inc, H2 2017
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, H2 2017
Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, H2 2017
Osteoarthritis Pain - Pipeline by Symic Biomedical Inc, H2 2017
Osteoarthritis Pain - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Osteoarthritis Pain - Dormant Projects, H2 2017
Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..1), H2 2017
Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..2), H2 2017
Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..3), H2 2017
Osteoarthritis Pain - Discontinued Products, H2 2017
Osteoarthritis Pain - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Osteoarthritis Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Achelios Therapeutics Inc
Addex Therapeutics Ltd
Allergan Plc
Ampio Pharmaceuticals Inc
Antibe Therapeutics Inc
Aralez Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
Axsome Therapeutics Inc
BELLUS Health Inc
Boehringer Ingelheim GmbH
Cara Therapeutics Inc
Centrexion Therapeutics Corp
Chromocell Corp
Elite Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Flexion Therapeutics Inc
Genzyme Corp
GlaxoSmithKline Plc
Grunenthal GmbH
Iroko Pharmaceuticals LLC
Marina Biotech Inc
Medestea Research & Production SpA
MedImmune LLC
Merck & Co Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
ProteoThera Inc
pSivida Corp
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Rottapharm Biotech Srl
Shionogi & Co Ltd
Symic Biomedical Inc
Taiwan Liposome Company Ltd
Vertex Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Skip to top


Inflammatory Pain - Pipeline Review, H2 2014 US$ 2,000.00 Jul, 2014 · 164 pages
Visceral Pain - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 55 pages
Visceral Pain - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 56 pages
Ocular Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 70 pages

Ask Your Question

Osteoarthritis Pain - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: